<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03537950</url>
  </required_header>
  <id_info>
    <org_study_id>HR15-162744</org_study_id>
    <nct_id>NCT03537950</nct_id>
  </id_info>
  <brief_title>Shifting Brain Excitation-Inhibition Balance in Autism Spectrum Disorder</brief_title>
  <official_title>Shifting Brain Excitation-Inhibition Balance Through the Endocannabinoid System in Men With Autism Spectrum Disorder (ASD) and in Healthy Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King's College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates brain response to single acute dose of cannabidiol, cannabidivarin,
      and placebo in healthy men with and without autism spectrum disorder
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous research suggests that cannabidiol (CBD) and cannabidivarin (CBDV) could have the
      potential to shift brain excitation and inhibition (E-I) in the healthy brain and in
      neurodevelopmental psychiatric conditions, where this balance is disrupted, such as autism
      spectrum disorder (ASD). However, no study to date has investigated this. Therefore, in this
      study, we invited 20 healthy men with and without ASD. Each participant received each drug
      once (600mg CBD/CBDV, or matched placebo) and magnetic resonance imaging was used to obtain
      measures of brain biochemistry, activity, and connectivity. We further obtained
      questionnaires, task data, saliva, urine and blood samples, and conducted visual tasks using
      eye tracking, electroencephalography, and retinal imaging.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 22, 2016</start_date>
  <completion_date type="Anticipated">April 27, 2019</completion_date>
  <primary_completion_date type="Actual">February 16, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Repeated-measures cross-over study, where each subject received each of three pharmacological probes once (order of drug administration was pseudorandomised)</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Participants and investigators were blinded to the drug condition.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Brain biochemistry response to pharmacological stimulation</measure>
    <time_frame>In the months 1-2 following the last day of scanning.</time_frame>
    <description>The measure of brain biochemistry response to PLC, CBD, and CBDV includes the following:
Assessment of the ratio of brain excitation and inhibition (measured as the balance of excitatory and inhibitory neurotransmitters) using using proton magnetic resonance spectroscopy [1H]MRS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of low frequency brain activity using resting state fMRI</measure>
    <time_frame>In the months 3-4 following the last day of scanning</time_frame>
    <description>In the third and fourth month following the day of the last scan, we will measure whole brain low frequency brain activity using resting state functional magnetic resonance imaging. Measure of activity: fractional amplitude of low frequency fluctuations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of brain functional connectivity using resting state fMRI</measure>
    <time_frame>In the months 5-6 following the last day of scanning</time_frame>
    <description>In the fifth and sixth month following the day of the last scan, we will measure whole brain resting state functional connectivity using resting state functional magnetic resonance imaging. Measure of connectivity: correlation between pairs of regions.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>PLC, CBD, CBDV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose order: PLC, CBD, CBDV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLC, CBDV, CBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose order: PL, CBDV, CBD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBD, PLC, CBDV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose order: CBD, PLC, CBDV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBD, CBDV, PLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose order: CBD, CBDV, PLC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBDV, PLC, CBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose order: CBDV, PLC, CBD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBDV, CBD, PLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose order: CBDV, CBD, PLC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLC</intervention_name>
    <description>Single oral dose of PLC.</description>
    <arm_group_label>PLC, CBD, CBDV</arm_group_label>
    <arm_group_label>PLC, CBDV, CBD</arm_group_label>
    <arm_group_label>CBD, PLC, CBDV</arm_group_label>
    <arm_group_label>CBD, CBDV, PLC</arm_group_label>
    <arm_group_label>CBDV, PLC, CBD</arm_group_label>
    <arm_group_label>CBDV, CBD, PLC</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBD</intervention_name>
    <description>Single oral dose of cannabidiol (CBD) - 600mg.</description>
    <arm_group_label>PLC, CBD, CBDV</arm_group_label>
    <arm_group_label>PLC, CBDV, CBD</arm_group_label>
    <arm_group_label>CBD, PLC, CBDV</arm_group_label>
    <arm_group_label>CBD, CBDV, PLC</arm_group_label>
    <arm_group_label>CBDV, PLC, CBD</arm_group_label>
    <arm_group_label>CBDV, CBD, PLC</arm_group_label>
    <other_name>Cannabidiol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBDV</intervention_name>
    <description>Single oral dose of cannabidivarin (CBDV) - 600mg.</description>
    <arm_group_label>PLC, CBD, CBDV</arm_group_label>
    <arm_group_label>PLC, CBDV, CBD</arm_group_label>
    <arm_group_label>CBD, PLC, CBDV</arm_group_label>
    <arm_group_label>CBD, CBDV, PLC</arm_group_label>
    <arm_group_label>CBDV, PLC, CBD</arm_group_label>
    <arm_group_label>CBDV, CBD, PLC</arm_group_label>
    <other_name>Cannabidivarin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  men

          -  pass diagnostic threshold for ASD on the ADI-R (if informant is available)

          -  currently symptomatic on ADOS

          -  age 18-50 years

          -  can give informed consent

          -  IQ&gt;70 (on a standard instrument such as WASI)

          -  medication-free in the month preceding participation (but regular medication with
             drug, which does not affect glutamate or GABA directly may be permitted)

          -  willing to provide urine samples to screen for use of illicit substances prior to each
             scan

        Exclusion Criteria:

          -  IQ&lt;70

          -  history of psychosis, co-morbid major mental illness, significant physical illness
             (heart disease, high blood pressure, seizures)

          -  habitual substance misuse (including alcohol)

          -  known allergy to cannabis

          -  ASD caused by a known genetic syndrome e.g. Fragile X or 22q11 deletion syndrome,

          -  past/present treatment for epilepsy

          -  Women will be excluded from this pilot study to reduce heterogeneity in a small
             sample; avoid the issues around exposing women of reproductive age to a drug; and
             because pregnancy is a routine exclusion criteria for research MRI. Lastly, ASD is
             more common in men.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grainne McAlonan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>King's College London</name>
      <address>
        <city>London</city>
        <zip>SE5 8AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2018</study_first_submitted>
  <study_first_submitted_qc>May 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2018</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King's College London</investigator_affiliation>
    <investigator_full_name>Dr Grainne McAlonan</investigator_full_name>
    <investigator_title>Deputy head of department</investigator_title>
  </responsible_party>
  <keyword>Cannabidiol</keyword>
  <keyword>Cannabidivarin</keyword>
  <keyword>E-I balance</keyword>
  <keyword>pharmacological imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

